Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pick 4 contest. Have to make this a reminder for next year...
This is SSKILLZ1's pick 4 contest board. If I have the time I'll compare mine to theirs and maybe even dd & play some of theirs.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167347839
Totally forgot that I had their board marked. Anyway, that's their list.
mine...
SNGX .69
LXRX 3.89
HEPA 1.14
RCAT 2.09
Tried to post Dec 31st, 2021 closing prices but may be off a tiny bit.
To compete against myself....
all cash...
CFRX 2.59
SONN .41
INPX .57
DYNT 1.00
If you're interested post your 2022 top 4 picks.
IPIX's PR from December's data on SA gets absolutely no comments. Actually it's the first time in a couple years I've even visited to review comments there. Nada. Not that I'm surprised.
https://seekingalpha.com/pr/18590051-innovation-pharmaceuticals-analyzing-full-dataset-for-brilacidin-covidminus-19-clinical-trial
Might be my last add here, $3.58. Gap from August filled. See if this holds the 3.58.
If anyone's looking, take a look at the Ichimoku charts as well. I see some decent basing potential. Otherwise the charts really aren't that appetizing. Until something happens. With low volume days it's easily manipulated.
I see no way of turning off the faucet. Not without a partnership or some major grants. Think we know how likely that is. A burn rate of 10.7 Mil is comparable to a legit small cap listed bio imo.
Anyway, I'm in the rafters looking down to see if Leo actually gets something going.
No position.
I finished my last swing early November and a couple more into mid November. I've been waiting to see if the volatility would pick back up again. Sometimes it's about the technical side, not the fundamentals. But for SURE, IPIX has helped pay for quite a nice piece of my current portfolio.
See if it ever does again.
Yes, they've stated that as one of the items to vote Feb 9th. The timeline goes into the summer to execute though there is certainly still the possibility the split won't be needed... IF "if" happens.
Be nice to see this puppy get its game on!!!! How bout some .27's!.
ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis
Source: GlobeNewswire Inc.?
ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that it has received an additional award from the Cystic Fibrosis Foundation (CFF). This contract award will support investigation of the potential utility of exebacase for treating serious lung infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (CF). The program, titled Nonclinical Assessment of Lysin Exebacase for Treating MRSA Infections in CF will, over the course of 12 months, evaluate the in vitro activity of exebacase against bacterial specimens obtained from CF patients.
“MRSA lung infections lead to potential acceleration in the decline in lung function and are an independent predictor of mortality in the CF population. Eradication of persistent MRSA in the lungs of CF patients remains a major challenge despite current antibiotic therapy. Thus, there is a pressing unmet need for new medical modalities and novel therapeutic approaches to address the serious health threat to CF patients,” said Cara Cassino, M.D., Executive Vice President of Research & Development and Chief Medical Officer of ContraFect. “We are pleased to have the opportunity to work with the CF Foundation again in order to evaluate the potential utility of exebacase as such a treatment for MRSA lung infections in this vulnerable population,” continued Dr. Cassino.
Pathogenic bacteria are known to be a major contributor to CF disease. The lungs of CF patients are typically colonized with pathogenic bacteria, that damage the epithelial surfaces. The growth of highly resistant Staph aureus or Pseudomonas aeruginosa, two of the most common causes of lung infections in CF patients, is associated with further epithelial surface damage, and potentially an overall decline in pulmonary function. MRSA has become more prevalent in the CF population in recent years, increasing from 9.2 percent in 2002 to 25.9 percent in 2017. MRSA plays a role in pulmonary exacerbations of CF that may require hospitalization and treatment with systemic antibiotics. Chronic lung infections are known to be the main cause of lung function deterioration, and ultimately mortality, in CF patients.
The award from the Cystic Fibrosis Foundation will provide ContraFect with financial support for research activities. Further financial details were not disclosed. ContraFect retains global rights for exebacase and its entire DLA therapeutic pipeline.
If this works out my 3.48's may see over $10.
Gap from last August fills 3.48. I'll bite.
On December 30, 2021, NovAccess Global Inc. (“NovAccess” or the “company”) obtained a $25,000 loan from each of Dwain K. Morris-Irvin, the company’s chief executive officer, Neil J. Laird, the company’s chief financial officer, and Amit Mulchandani, chief executive officer of Letzhangout, LLC, a company that provides accounting consulting services to NovAccess (collectively, the “Loans”). NovAccess issued to each of Messrs. Irvin, Laird and Mulchandani a demand promissory note for $25,000 evidencing the Loans (Collectively, the “Notes”). The Notes are due on demand and bear interest at 10% per year. NovAccess will use the $75,000 proceeds of the Loans to retire the loan from Power Up Lending Group Ltd. and for general working capital purposes.
https://ih.advfn.com/stock-market/USOTC/novaccess-global-pk-XSNX/stock-news/86928970/current-report-filing-8-k
See yesterday's 8k. 25k for 10% interest per year divi? And going debt free for the company? That's a pretty good start imo.
Thinking we'll see Friday afternoon discounts then next week the PRs start rolling in. ??
VP, HUMAN RESOURCES form 3 filed. Initial statement.
Interesting.
Ya, don't take your eyes off this puppy. I'm seeing this as a near term multi bagger with merge potential.
Jmho
Keep the news alerts set.
I'll add that we have no control over the hedge fund manipulation, and what's the short interest here? Check it out. When anything major happens we'll see this change in a hurry.
Again, just my opinion.
Energous and Syntiant Collaborate for Wireless Charging of Always-on Edge AI Processors
Source: Business Wire
Companies to Demonstrate Energous’ WattUp PowerBridge Technology Combined With Syntiant's Ultra-Low-Power Deep Learning Architecture for IoT Network Edge Applications at CES 2022
Energous Corporation (Nasdaq: WATT), a leading developer of RF-based charging for wireless power networks, today announced a collaboration with Syntiant, a provider of deep learning solutions making edge AI a reality for always-on voice, sensor and image applications, to develop and implement Energous’ WattUp wireless power network technology with Syntiant’s Neural Decision Processors™ (NDPs) for edge artificial intelligence (AI) deployments across a wide range of consumer and industrial use cases.
Demonstrations of the Energous and Syntiant technology will take place January 5-8 during CES 2022 in Las Vegas at the Energous booth (#51965) located on the show floor of the Venetian Expo Hall (formerly the Sands Convention Center).
California-based Syntiant combines the industry’s most efficient silicon with a data platform and training pipeline, providing customers with low-cost, turn-key solutions that put deep learning processing into almost any edge device, free from cloud connectivity, ensuring privacy and security. The company’s ultra-low-power NDPs are being designed into earbuds, wearables, medical devices, mobile phones, laptops, smart home appliances, as well as industrial IoT equipment and automobiles. Designed by applying a clean-sheet, hardware/software co-design methodology, Syntiant’s AI processors deliver 100x more efficiency and 10x the throughput compared to current low-power microcontroller unit solutions.
“Deployment of IoT edge devices for industrial, retail and other applications is expanding as they enable new data processing capabilities,” said Cesar Johnston, CEO of Energous. “With this expansion, however, comes concerns around delivering guaranteed levels of power to these billions of devices that are often significant distances away from a reliable power source. Our collaboration with Syntiant is aimed at addressing this challenge by integrating our WattUp receiver technology with Syntiant’s deep learning technology for edge AI applications, enabling them to harvest RF-based energy from Energous WattUp PowerBridge transmitters.”
“Syntiant’s Neural Decision Processors help reduce infrastructure costs by moving AI processing from the cloud to the edge, reliably, securely and with nominal power consumption,” said Kurt Busch, CEO of Syntiant. “We share a similar perspective with Energous that much of tomorrow’s innovation is happening at the edge, and our collaboration will successfully demonstrate both technologies working together, delivering power where it is not, while providing highly accurate, cloud-free inference across a wide range of consumer and industrial applications.”
Unlike passive solutions that harvest ambient energy from the surrounding environment, which typically offer extremely low amounts of power and can be unpredictable in terms of how much power is available, Energous’ wireless power network solutions include a WattUp PowerBridge transmitter that emits conducted RF power in a specific area or direction. This RF-based energy is then harvested by receiving devices. Energous’ wireless power networks support “one to many” charging, allowing multiple devices to be simultaneously charged from a single transmitter. It is applicable to a wide range of industries and applications, from drug storage monitors and patient trackers in a healthcare setting, to smoke detectors and motion sensors in a smart home, to fault prevention, temperature and other safety sensors in an industrial environment.
For more information on Energous WattUp or to request a developer kit, please visit energous.com.
About Syntiant
Founded in 2017 and headquartered in Irvine, Calif., Syntiant Corp. is a leader in delivering end-to-end deep learning solutions for always-on applications by combining purpose-built silicon with an edge-optimized data platform
Hey surfer! Man it's been a while! Yes, I like the potential here going into this summer. I think they'll have a much better footprint by then.
Correction: the sabby reference is not for BXRX. Mixed my DD with another bio. But the pinch is still very relevant. Until it isn't.
Giddy up!! $SNGX Dusquetide previously demonstrated benefits in reducing the duration of severe oral mucositis (SOM) in a Phase 2 clinical trial and reduction in SOM rates in the per protocol population in a Phase 3 study. In addition to the reduction of severe oral mucositis, an acceleration in the clearance of tumor response and an increase in overall survival were also observed in the Phase 2 clinical study as an ancillary benefit to treating oral mucositis in patients receiving chemo-radiation for their head and neck cancer (HNC).
https://finance.yahoo.com/news/dusquetide-demonstrates-positive-anti-tumor-123000840.html
I have two things on my mind here. 1st is the amended form 13. Sabby has been one to watch for, how do I put it, well... sometimes when Sabby takes a position after a period of time there's quite the push. Noting that the company announced in their form 14 a reverse split (meeting in February) may take the thunder out of a major move, there could still be one that negates the need for the split. Fine with me.
Second, the chart is poised for a very powerful potential pinch. It's just after the New Year so tax selloff is now complete. A pinch with some solid news to keep the momentum going (an excellent article even) would be the fire that makes it happen.
https://ih.advfn.com/stock-market/NASDAQ/hepion-pharmaceuticals-HEPA/stock-news/86933501/amended-statement-of-ownership-sc-13g-a
BXRX daily
All my opinion of course.
LXRX 3.89 Lexicon (LXRX) Submits NDA to the FDA for Cardiovascular Drug
https://finance.yahoo.com/news/lexicon-lxrx-submits-nda-fda-154603010.html
That's just AWESOME!!!!!
LET'S ROCK!!! $SNGX
Don't let the price action fool you, play wisely of course but if they do get the nod from the FDA, there'll be plenty left in the dust.
https://ih.advfn.com/p.php?pid=nmona&article=86915286
imo
Also,, note the low volume manipulation.
BXRX .227 Tightening up nicely.
BXRX daily
Happy New Year!
Yes, I'm still here.
Multi bagger imo
Merry Christmas yo all of you.
Not just those that followed me into riches or poorer but I wanted to pass my love to all of you.
On a side note, as we all know, we deal with loss. Friends an family.
There are some great outlets that I'm always supporting. NAMNI
They reach more than you can even think of though you never see them.
Merry Christmas
Excellent day!
Just about 40M volume. Excellent.
That would be a trip for sure!!
IT'S COMING!!!!!
Major volume on RCAT. Consolidating a bit, may bull into the close.
https://finance.yahoo.com/news/red-cat-holdings-awarded-customs-110000482.html
Coming up on 34M volume. Tomorrow may get a bit more volatile. Revenue is only just starting to kick in and I'm thinking MORE institutional buying is just around the corner as well.
https://finviz.com/quote.ashx?t=RCAT
Inst Own 17.80%
Inst Trans +440.37%
25.34M Nice day!!!
Let's go for 50M volume!! Run this puppy!!
Red Cat Holdings Awarded Customs and Border Protection Contract Worth up to $90 Million over Five Years
Wed, December 22, 2021, 6:00 AM
"We look forward to fulfilling all orders placed under this agreement, along with any others that we may receive, and making full use of Teal's new 26,000-square foot facility in Salt Lake City. Given the security mandates within the Department of Defense and Federal Government, as well as the recently passed infrastructure bill that has a 'Build America Buy America' mandate, we are confident in our ability to offer domestically-sourced drone solutions and services across both Enterprise and Government applications."
https://finance.yahoo.com/news/red-cat-holdings-awarded-customs-110000482.html
$8 target. jmho. Merry Christmas!
What is the Stock Market?
The stock market refers to public markets that exist for issuing, buying, and selling stocks that trade on a stock exchange or over-the-counter. Stocks, also known as equities, represent fractional ownership in a company, and the stock market is a place where investors can buy and sell ownership of such investible assets. An efficiently functioning stock market is considered critical to economic development, as it gives companies the ability to quickly access capital from the public.
Stock Market - the floor on the NYSE
Purposes of the Stock Market – Capital and Investment Income
The stock market serves two very important purposes. The first is to provide capital to companies that they can use to fund and expand their businesses. If a company issues one million shares of stock that initially sell for $10 a share, then that provides the company with $10 million of capital that it can use to grow its business (minus whatever fees the company pays for an investment bank to manage the stock offering). By offering stock shares instead of borrowing the capital needed for expansion, the company avoids incurring debt and paying interest charges on that debt.
The secondary purpose the stock market serves is to give investors – those who purchase stocks – the opportunity to share in the profits of publicly-traded companies. Investors can profit from stock buying in one of two ways. Some stocks pay regular dividends (a given amount of money per share of stock someone owns). The other way investors can profit from buying stocks is by selling their stock for a profit if the stock price increases from their purchase price. For example, if an investor buys shares of a company’s stock at $10 a share and the price of the stock subsequently rises to $15 a share, the investor can then realize a 50% profit on their investment by selling their shares.
History of Stock Trading
Although stock trading dates back as far as the mid-1500s in Antwerp, modern stock trading is generally recognized as starting with the trading of shares in the East India Company in London.
The Early Days of Investment Trading
Throughout the 1600s, British, French, and Dutch governments provided charters to a number of companies that included East India in the name. All goods brought back from the East were transported by sea, involving risky trips often threatened by severe storms and pirates. To mitigate these risks, ship owners regularly sought out investors to proffer financing collateral for a voyage. In return, investors received a portion of the monetary returns realized if the ship made it back successfully, loaded with goods for sale. These are the earliest examples of limited liability companies (LLCs), and many held together only long enough for one voyage.
The East India Company
The formation of the East India Company in London eventually led to a new investment model, with importing companies offering stocks that essentially represented a fractional ownership interest in the company, and that therefore offered investors investment returns on proceeds from all the voyages a company funded, instead of just on a single trip. The new business model made it possible for companies to ask for larger investments per share, enabling them to easily increase the size of their shipping fleets. Investing in such companies, which were often protected from competition by royally-issued charters, became very popular due to the fact that investors could potentially realize massive profits on their investments.
The First Shares and the First Exchange
Company shares were issued on paper, enabling investors to trade shares back and forth with other investors, but regulated exchanges did not exist until the formation of the London Stock Exchange (LSE) in 1773. Although a significant amount of financial turmoil followed the immediate establishment of the LSE, exchange trading overall managed to survive and grow throughout the 1800s.
Anyway, I'm all for seeing this play work out. I think they're positioned to start making things happen that draws the right crowd.
Exactly what I was talking about. 500+ point swings on the intraday for the DJI.
Just wait till we see closer to 1000 points with potential market halts.
Again, know what you own. If the fundamentals are solid I'm thinking you're good though cash is king as well.
Thinking January is going to be the *****.
https://finviz.com/futures_charts.ashx?p=d1&t=YM
I think it's excellent and shows excellent potential. Todays price action is very interesting as well. I wasn't really expecting anything in this sector until after the New Year. The chart shows this right at the short term trend line resistance. 2 trading days left till Christmas break! Enjoy and be safe! A close 2.80 or better Thursday and it's game on imo.